Stock Scorecard
Stock Summary for LAVA Therapeutics NV (LVTX) - $1.29 as of 3/26/2025 12:59:59 AM EST
Total Score
11 out of 30
Safety Score
20 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for LVTX
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for LVTX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for LVTX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for LVTX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for LVTX (20 out of 100)
| Stock Price Rating (Max of 10) | 2 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 2 |
| Analyst Buy Ratings (Max of 5) | 2 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for LVTX
Financial Details for LVTX
Company Overview |
|
|---|---|
| Ticker | LVTX |
| Company Name | LAVA Therapeutics NV |
| Country | USA |
| Description | Lava Therapeutics BV, a biotechnology company, is dedicated to developing a portfolio of gamma-delta bispecific T-cell activators (gamma-delta bsTCE) for the treatment of solid tumors and hematologic malignancies based on its platform. The company is headquartered in Utrecht, the Netherlands. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 9/30/2024 |
| Next Earnings Date | 5/19/2025 |
Stock Price History |
|
| Last Day Price | 1.29 |
| Price 4 Years Ago | 5.50 |
| Last Day Price Updated | 3/26/2025 12:59:59 AM EST |
| Last Day Volume | 126,352 |
| Average Daily Volume | 802,561 |
| 52-Week High | 4.21 |
| 52-Week Low | 0.85 |
| Last Price to 52 Week Low | 51.76% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 36.51 |
| Sector PE | 40.40 |
| 5-Year Average PE | -1.32 |
| Free Cash Flow Ratio | 1.25 |
| Industry Free Cash Flow Ratio | 11.75 |
| Sector Free Cash Flow Ratio | 47.07 |
| Current Ratio Most Recent Quarter | 5.36 |
| Total Cash Per Share | 1.03 |
| Book Value Per Share Most Recent Quarter | 1.25 |
| Price to Book Ratio | 1.04 |
| Industry Price to Book Ratio | 8.88 |
| Sector Price to Book Ratio | 21.82 |
| Price to Sales Ratio Twelve Trailing Months | 4.66 |
| Industry Price to Sales Ratio Twelve Trailing Months | 86.87 |
| Sector Price to Sales Ratio Twelve Trailing Months | 27.97 |
| Analyst Buy Ratings | 1 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 26,298,700 |
| Market Capitalization | 33,925,323 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -31.55% |
| Reported EPS 12 Trailing Months | -1.01 |
| Reported EPS Past Year | -0.76 |
| Reported EPS Prior Year | -1.59 |
| Net Income Twelve Trailing Months | -27,643,000 |
| Net Income Past Year | -41,974,000 |
| Net Income Prior Year | -31,907,000 |
| Quarterly Revenue Growth YOY | 471.20% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | -381.70% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 26,963,000 |
| Total Cash Past Year | 44,231,000 |
| Total Cash Prior Year | 100,333,000 |
| Net Cash Position Most Recent Quarter | 26,963,000 |
| Net Cash Position Past Year | 39,591,000 |
| Long Term Debt Past Year | 4,640,000 |
| Long Term Debt Prior Year | 4,640,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 0.92 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 51,178,000 |
| Total Stockholder Equity Prior Year | 86,040,000 |
| Total Stockholder Equity Most Recent Quarter | 32,993,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -28,290,759 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.08 |
| Free Cash Flow Past Year | -39,702,000 |
| Free Cash Flow Prior Year | 3,456,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.05 |
| MACD Signal | 0.07 |
| 20-Day Bollinger Lower Band | 0.68 |
| 20-Day Bollinger Middle Band | 1.20 |
| 20-Day Bollinger Upper Band | 1.73 |
| Beta | 0.48 |
| RSI | 57.17 |
| 50-Day SMA | 2.31 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 3.38 |
System |
|
| Modified | 3/26/2025 1:00:45 AM EST |